Literature DB >> 15970715

The effects of high-dose heparin on inflammatory and coagulation parameters following cardiopulmonary bypass.

Domenico Paparella1, Osman O Al Radi, Qing H Meng, Thomas Venner, Kevin Teoh, Edward Young.   

Abstract

Systemic inflammation and the activation of the coagulation system following cardiopulmonary bypass (CPB) may contribute to postoperative complications. In vitro studies have demonstrated that heparin possesses anti-inflammatory properties. To ascertain the relative benefits of high versus low heparin doses, we studied the impact of varying heparin doses on the inflammatory response and coagulation system during and following CPB. Forty patients scheduled for elective coronary artery bypass surgery requiring CPB were randomized to either a low dose (300 U/kg) (Group L) or a high dose of unfractionated heparin (600 U/kg) (Group H). To evaluate the inflammatory response, proinflammatory cytokines [tumor necrosis factor-alpha and interleukin-6 (IL-6)] were measured at four different times: before CPB (T0), 30 min after the institution of CPB (T1), 30 min after cross-clamp release (T2), and 4 h after the end of CPB (T3). Thrombin-antithrombin complex, platelet factor 4 and anti-activated factor X heparin concentrations were also measured. Patients in Group H received greater heparin (44.934 U versus 27.741 U, P<0.001) and protamine (P=0.003) doses. Postoperative blood loss and blood products transfusions were not significantly different in the groups. At T1, mean heparin plasma concentration was higher in Group H (P<0.001). IL-6 was significantly lower in Group H compared with Group L (P=0.01) only at T1. Using a mixed-effects statistical model, tumor necrosis factor-alpha and IL-6 levels were comparable regardless of the heparin dose. Thrombin-antithrombin complex levels were lower in Group H (P=0.04) and platelet factor 4 levels were significantly lower in Group H at T2 (P=0.04). Higher heparin doses were associated with higher heparin concentrations during CPB. A high heparin dose achieved a better preservation of the coagulation system with less thrombin formation and platelet activation. The heparin dose had small influence on proinflammatory cytokines release.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970715     DOI: 10.1097/01.mbc.0000172328.58506.4a

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  4 in total

1.  Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?

Authors:  Bruce D Spiess
Journal:  J Extra Corpor Technol       Date:  2011-03

2.  Antithrombin after cardiac surgery: implications on short and mid-term outcome.

Authors:  Domenico Paparella; Giangiuseppe Cappabianca; Giuseppe Scrascia; Giuseppe Fiore; Andreas Paramythiotis; Nicola Di Bari; Maria Pia Trisorio Liuzzi; Mohamed F Ibrahim; Tommaso Fiore; Luigi de Luca Tupputi Schinosa
Journal:  J Thromb Thrombolysis       Date:  2008-01-11       Impact factor: 2.300

3.  A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients.

Authors:  Gregory A Nuttall; Mark M Smith; Bradford B Smith; Jon M Christensen; Paula J Santrach; Hartzell V Schaff
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-12-22       Impact factor: 1.889

Review 4.  Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review.

Authors:  Sarah Mousavi; Mandana Moradi; Tina Khorshidahmad; Maryam Motamedi
Journal:  Adv Pharmacol Sci       Date:  2015-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.